Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

13,052 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma.
Lee A, Duggan S, Deeks ED. Lee A, et al. Drugs. 2020 Jun;80(8):813-819. doi: 10.1007/s40265-020-01302-2. Drugs. 2020. PMID: 32306208 Review.
In this pivotal trial, treatment with intravenous cemiplimab 3 mg/kg once every 2 weeks or 350 mg once every 3 weeks resulted in a clinically significant objective response rate across laCSCC and mCSCC patient groups. ...Overall, cemiplimab has a durable, clinically …
In this pivotal trial, treatment with intravenous cemiplimab 3 mg/kg once every 2 weeks or 350 mg once every 3 weeks resulted in a cl …
Tucatinib: First Approval.
Lee A. Lee A. Drugs. 2020 Jul;80(10):1033-1038. doi: 10.1007/s40265-020-01340-w. Drugs. 2020. PMID: 32548668 Review.
Tucatinib is an oral, small molecule, selective HER2 inhibitor initially developed by Array BioPharma (a subsidiary of Pfizer) and subsequently developed by Seattle Genetics for the treatment of HER2-positive solid tumours, including breast cancer and colorectal cancer. .. …
Tucatinib is an oral, small molecule, selective HER2 inhibitor initially developed by Array BioPharma (a subsidiary of Pfizer) and su …
Dexamethasone Intracanalicular Insert: A Review in Treating Post-Surgical Ocular Pain and Inflammation.
Lee A, Blair HA. Lee A, et al. Drugs. 2020 Jul;80(11):1101-1108. doi: 10.1007/s40265-020-01344-6. Drugs. 2020. PMID: 32588339 Free PMC article. Review.
A significantly higher proportion of patients treated with the dexamethasone intracanalicular insert than with the placebo insert had no pain at day 8 (co-primary endpoint, 7 days post-operation) across three pivotal phase III trials, and the inflammation co-primary endpoi
A significantly higher proportion of patients treated with the dexamethasone intracanalicular insert than with the placebo insert had
Correction to: Dexamethasone Intracanalicular Insert: A Review in Treating Post-Surgical Ocular Pain and Inflammation.
Lee A, Blair HA. Lee A, et al. Drugs. 2020 Aug;80(12):1265. doi: 10.1007/s40265-020-01366-0. Drugs. 2020. PMID: 32700064
The article Dexamethasone Intracanalicular Insert: A Review in Treating Post-Surgical Ocular Pain and Inflammation, written by Arnold Lee and Hannah A. ...
The article Dexamethasone Intracanalicular Insert: A Review in Treating Post-Surgical Ocular Pain and Inflammation, written by Arnold …
Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis.
Lee A, Scott LJ. Lee A, et al. BioDrugs. 2020 Apr;34(2):235-244. doi: 10.1007/s40259-020-00416-z. BioDrugs. 2020. PMID: 32207094 Review.
In pivotal phase III trials in adults with moderate to severe plaque psoriasis, significantly more patients receiving certolizumab pegol 200 mg or 400 mg once every 2 weeks than placebo recipients achieved a ≥ 75% reduction in PASI score (PASI75 responder) and a PGA …
In pivotal phase III trials in adults with moderate to severe plaque psoriasis, significantly more patients receiving certolizumab pegol 200 …
Spontaneous healing of human amnion in the premature rupture of membrane model.
Lee AY, Ryu KJ, Ahn KH, Kang D, Geum DH, Kim BS, Cho GJ, Oh MJ, Kim HJ, Hong SC. Lee AY, et al. Placenta. 2020 Aug;97:29-35. doi: 10.1016/j.placenta.2020.06.009. Epub 2020 Jun 15. Placenta. 2020. PMID: 32792059
Clinical course and physiotherapy intervention in 9 patients with COVID-19.
Lee AJY, Chung CLH, Young BE, Ling LM, Ho BCH, Puah SH, Iqbal SR, Tan GP. Lee AJY, et al. Physiotherapy. 2020 Jun 27;109:1-3. doi: 10.1016/j.physio.2020.06.002. Online ahead of print. Physiotherapy. 2020. PMID: 32791333
NMDA receptor partial agonist GLYX-13 alleviates chronic stress-induced depression-like behavior through enhancement of AMPA receptor function in the periaqueductal gray.
Yang PS, Peng HY, Lin TB, Hsieh MC, Lai CY, Lee AS, Wang HH, Ho YC. Yang PS, et al. Among authors: lee as. Neuropharmacology. 2020 Aug 10:108269. doi: 10.1016/j.neuropharm.2020.108269. Online ahead of print. Neuropharmacology. 2020. PMID: 32791085
A recombinant human immunoglobulin with coherent avidity to hepatitis B virus surface antigens of various viral genotypes and clinical mutants.
Jeong GU, Ahn BY, Jung J, Kim H, Kim TH, Kim W, Lee A, Lee K, Kim JH. Jeong GU, et al. Among authors: lee a. PLoS One. 2020 Aug 13;15(8):e0236704. doi: 10.1371/journal.pone.0236704. eCollection 2020. PLoS One. 2020. PMID: 32790777
13,052 results
Jump to page
Feedback